Naglazyme


Indications and Reactions:

Role Indications Reactions
Primary
Mucopolysaccharidosis Vi 71.6%
Product Used For Unknown Indication 15.9%
Premedication 5.9%
Mucopolysaccharidosis Iv 1.8%
Mucopolysaccharidosis 0.9%
Pyrexia 0.5%
Cardiac Disorder 0.4%
Nasal Congestion 0.4%
Attention Deficit/hyperactivity Disorder 0.3%
Cardiac Valve Disease 0.3%
Pain 0.3%
Asthma 0.2%
Infusion Related Reaction 0.2%
Pharyngotonsillitis 0.2%
Rash 0.2%
Viral Infection 0.2%
Constipation 0.1%
Device Occlusion 0.1%
Metabolic Disorder 0.1%
Neurogenic Bladder 0.1%
Pneumonia 26.2%
Spinal Cord Compression 17.6%
Convulsion 6.6%
Cervical Cord Compression 5.5%
Vomiting 5.2%
Death 4.6%
Respiratory Failure 3.7%
Sepsis 3.7%
Pyrexia 3.5%
Intracranial Pressure Increased 2.9%
Bronchospasm 2.6%
Hydrocephalus 2.6%
Urticaria 2.3%
Sleep Apnoea Syndrome 2.0%
Umbilical Hernia 2.0%
Upper Respiratory Tract Infection 2.0%
Cardio-respiratory Arrest 1.7%
Influenza 1.7%
Infusion Related Reaction 1.7%
Nephrotic Syndrome 1.7%
Secondary
Mucopolysaccharidosis Vi 70.8%
Premedication 16.7%
Attention Deficit/hyperactivity Disorder 6.3%
Product Used For Unknown Indication 4.2%
Prophylaxis 2.1%
Pneumonia 30.3%
Bladder Disorder 12.1%
Urticaria 9.1%
Acute Respiratory Failure 6.1%
Blindness 6.1%
Deafness 6.1%
Influenza 6.1%
Liver Injury 6.1%
Muscle Spasticity 3.0%
Sepsis 3.0%
Sodium Retention 3.0%
Spinal Cord Compression 3.0%
Unresponsive To Stimuli 3.0%
Vomiting 3.0%

Drug Data